As seen in the chart below, it appears that renewable oil producer Solazyme (SZYM) has begun to stand apart from its supposed industry peer group over the last few months. Although often lumped together with struggling advanced biofuel and biochemical producers such as Amyris (AMRS), Gevo (GEVO), and KiOR (KIOR), Solazyme has begun to distinguish itself as investors begin to comprehend the vast distinctions between these companies. Apart from its superior balance sheet, operational traction, and magnetic appeal to landing industry-leading partners, Solazyme's comparative advantage is beginning to be understood in the company's biotechnology toolkit.
Over the past decade, Solazyme has refined...
Only subscribers can access this article, which is part of the PRO research library covering 3,589 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: